On January 27, Humana’s stock tumbled 21% in a single session, marking one of the largest one-day declines in the company’s history. The sell-off erased roughly $15 billion in market capitalization and came after analysts raised concerns over enrollment trends in Medicare Advantage plans. Investors noted that nearly 85% of Humana’s revenue is derived from its Medicare Advantage business, making the company particularly sensitive to changes in program rules and enrollment growth forecasts. Trading volume on the New York Stock Exchange surged to over 12 million shares, more than double its 30-day average, as hedge funds and retail investors alike adjusted their positions in response to downgrades by three major brokerage firms.

In pre-market trading on the following day, Humana shares fell an additional 13.49% after the administration proposed a 0.09% net average increase in Medicare Advantage payment rates for 2027—well below the 4% to 6% rise anticipated by Wall Street. The proposal translates to roughly $130 million in additional premiums for Humana, compared to analyst models calling for up to $900 million. Industry participants warn that flat payment growth could pressure operating margins, which stood at 4.8% in the fourth quarter of 2025. Humana’s chief financial officer indicated that management will review expense initiatives and provider network negotiations to offset the shortfall.

After the sharp declines, Humana trades near $200 per share, bringing its forward price-to-earnings ratio to approximately 10x, compared with a five-year average of 12x. Proponents argue that a disciplined cost structure—evidenced by a 2.1% medical loss ratio improvement in 2025—supports upside if payment rates stabilize. Skeptics counter that enrollment growth could slow to low single digits as competition intensifies, and that modest regulatory increases may not cover rising medical cost trends, which accelerated to 6.5% year-over-year in the fourth quarter. Portfolio managers are divided: one large asset manager recently trimmed its position by 30%, while another added to holdings on the belief that the risk/reward profile has become attractive.